Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors
August 24, 2020 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
August 18, 2020 14:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection
April 06, 2020 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, April 06, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease
December 18, 2019 17:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform...
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
July 23, 2019 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
First stage of Qu Biologics’ clinical trial assessing mucosal healing for novel immunotherapy for Crohn’s disease reaches 50% enrolment
November 13, 2018 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics’ Site Specific Immunomodulators Enhance Adoptive T cell Therapies in Solid Tumours
November 05, 2018 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Researchers discover that activating innate immunity in the gastrointestinal tract reduces disease pathology in ulcerative colitis
October 01, 2018 07:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics enrolls the first patient in new Phase 2 Crohn’s Disease clinical trial
July 25, 2018 12:53 ET
|
Qu Biologics
VANCOUVER, British Columbia, July 25, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Leading-edge Scientists in Innate Immunity Join Qu Biologics’ Scientific Advisory Board
May 15, 2018 13:34 ET
|
Qu Biologics
VANCOUVER, British Columbia, May 15, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...